Clinical trial · no report yet · Phase 2
NCT05361720
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- NCT05361720 ↗
- Recruiting
- Vanderbilt-Ingram Cancer Center
- 29 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 7 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Cabozantinib; Ipilimumab; Nivolumab
- Arms
- Arm I (ipilimumab, nivolumab) · Experimental
- Arm II (nivolumab, cabozantinib) · Experimental
- Enrollment
- 54 (estimated)
- Primary outcomes
- Overall response rate (ORR) (Arm 1)
- Overall response rate (Arm 2)
- Sponsor
- Vanderbilt-Ingram Cancer Center with National Cancer Institute (NCI), United States Department of Defense
- Start
- Dec 6, 2022
- Primary completion
- Oct 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05361720 · updated Aug 19, 2026